Overview

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: - obinutuzumab - venetoclax - acalabrutinib
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Genentech, Inc.
Treatments:
Acalabrutinib
Obinutuzumab
Venetoclax